Novartis shares plunged after late-stage failures of pelacarsen and del-desiran, impacting its long-term growth outlook. Despite setbacks, Novartis reiterated 2025-2030 revenue growth guidance of 5-6% CAGR, aided by Rhapsido's phase 3 success in RMS. Rhapsido's positive data in relapsing multiple sclerosis offer partial offset, with potential for $3 billion+ in annual peak sales.
Bitmine bought 28,086 ETH, boosting its treasury to 5.93 million tokens worth $14.8 billion and representing 4.9% of Ethereum's total supply.
Stitch Fix remains a 'hold' as I await further evidence of a sustained turnaround in active client growth and profitability. Despite continued declines in active clients, SFIX has achieved top-line growth and margin improvement through higher revenue per user and category expansion. Management guides for FY2026 revenue of $1.346–$1.351 billion and EBITDA of $49–$52 million, highlighting robust demand in activewear and men's categories.
The companies said the deal will help meet surging demand for consumer broadband and converged services, accelerating Verizon's push to bring internet access to more homes and businesses across the nation.
Nebius targets $3.0-$3.4 billion 2026 revenue and a $7-$9 billion exit run rate as AI capacity expands. Connected power could reach 800 MW-1 GW by year-end, while contracted power targets have increased substantially to 5 GW. Customer prepayments may exceed $9 billion in 2026, with recent contracts covering roughly 50%-60% of associated infrastructure CapEx.
Trex Company is upgraded to a soft ‘buy' based on favorable long-term risk/reward despite near-term profitability pressures. TREX benefits from strong exposure to the resilient repair and remodeling market, supported by high U.S. home equity and aging decks. Management targets $2B annual revenue by 2030, with $1.8–$2.2B capital deployment focused on organic growth, M&A, and buybacks.
Gold remains caught near $4,450, with the 50-day EMA offering support and $4,500 limiting upside momentum. CPI, central bank policy and geopolitical risks could determine whether the tight market finally breaks directionally.
Qualcomm shares have missed out on the chip sector's big rally this year. The company is now working on various chip projects with Amazon.
TPR's overseas growth accelerates on gains in China and Europe, with customer acquisition and brand relevance supporting fiscal 2027 expansion.
The AI infrastructure space features many companies that are growing at a dramatic clip. However, growth alone is often not enough to satisfy many investors.
Meta's ad engine is accelerating at a historic pace while the stock sits near a level that has historically signaled a cyclical floor, but the $130 billion capex bet hanging over the company changes every calculation an investor needs to
Oracle faces intense investor scrutiny after Q4 FY26, with credit downgrades and widening CDS spreads pressuring the stock to new lows. ORCL's capex-driven negative free cash flow and reliance on debt/equity funding, especially with a concentrated backlog from OpenAI, heighten downgrade risk. To regain momentum, ORCL must deliver accelerated Q1 FY27 revenue growth indicating faster backlog conversion and raise full-year guidance while avoiding EBITDA misses.
Tesla (NASDAQ: TSLA | TSLA Price Prediction) got some bad news. Its retail sales in China fell 12.4% in August.
Alvopetro Energy Ltd (TSX-V:ALV, OTC:ALVOF, FRA:A6Y0) announced that it has entered into an agreement with Courser Energy to add 28 gross sections, or 14 net sections, of heavy oil lands in Alberta's Mannville fairway. Under the agreement, Alvopetro will drill five earning wells beginning in the fourth quarter of 2026 at an estimated cost of C$8.5 million.
Medicus Pharma (NASDAQ:MDCX) is repositioning itself as a precision oncology-led biotechnology company, centering its strategy on CD228V, a second-generation antibody-drug conjugate targeting CD228-expressing solid tumors, the company said Tuesday. CD228V is now the company's principal strategic priority, with initial development focused on establishing clinical proof-of-concept in a selected tumor population.
MRK trades near its 52-week high as Keytruda drives growth, while its pipeline and new products offer a path beyond the 2028 patent cliff.
Western Digital is poised to benefit from AI-driven data growth as inference, Agentic AI and emerging workloads fuel long-term storage demand.
Tether's decentralized search engine could challenge tech giants, promoting privacy and reducing reliance on centralized data control. Tether is building a peer-to-peer search engine, and it already has a working demo.
Palantir's blowout growth numbers look like pure software success, but a closer look at how the company actually wins its deals reveals a business model that the current valuation may be dangerously misreading.
XRPH Wallet was taken offline after 4,011 accounts were drained of 267,664 XRP and other tokens, exposing risks at the app layer, not XRPL itself.
Salesforce just posted an earnings beat that sent the stock surging 34%, but the source of that surprise raises questions every investor should answer before buying in at these levels.
Crypto analyst Ali Martinez expects a potential 5% rally for XRP price if it breaks out of its descending triangle in the short time frame.
CAPL and GLP bring distinct strengths in income, scale, leverage and valuation, setting up a closer comparison for energy MLP investors.
CRTO, DIN and LNWO have been added to the Zacks Rank #5 (Strong Sell) List on September 8, 2026.
Three dividend growth stocks are here to offer income and growth potential as interest rates may stay higher for longer.
Zacks spotlights Oportun Financial, Uranium Royalty and Amgen, alongside standout gains from its key stock portfolios.
The Standard & Poor's 500 Index (SPX-7,718.60) May through July range has turned into an August-September consolidation, with roughly 200 SPX points separating the low and high ends of the ranges in both cases.
A deepened High-NA EUV collaboration is lifting Intel (NASDAQ:INTC | INTC Price Prediction) and ASML Holding (NASDAQ:ASML) in Tuesday morning trading, with the semiconductor equipment story cutting against a softer market backdrop.
SMCI, ADM, ALL, CNC and AVT are five undervalued stocks with strong estimate revisions and growth prospects that could offer more upside in 2026.
Lilly is expanding its neuroscience pipeline through strong growth and M&A, aiming to build a new long-term driver beyond cardiometabolic therapies.